135 related articles for article (PubMed ID: 2895125)
1. Pharmacokinetics and pharmacodynamics of oral nizatidine.
Vargas R; Ryan J; McMahon FG; Regel G; Offen WW; Matsumoto C
J Clin Pharmacol; 1988 Jan; 28(1):71-5. PubMed ID: 2895125
[TBL] [Abstract][Full Text] [Related]
2. Nocturnal acid suppression with a new H2 receptor antagonist--nizatidine.
Dammann HG; Gottlieb WR; Walter TA; Dreyer M; Müller P; Simon B; Keohane P
Hepatogastroenterology; 1986 Oct; 33(5):217-20. PubMed ID: 2879782
[TBL] [Abstract][Full Text] [Related]
3. Effect of nizatidine and cimetidine on betazole-stimulated gastric secretion of normal subjects: comparison of effects on acid, water, and pepsin.
Hammond JB; Offen WW
Am J Gastroenterol; 1988 Jan; 83(1):32-6. PubMed ID: 2892392
[TBL] [Abstract][Full Text] [Related]
4. [Inhibition of 24-hour acidity by nizatidine].
Dammann HG; Dreyer M; Gottlieb WR; Wolf N; Müller P; Simon B
Fortschr Med; 1989 May; 107(14):321-4. PubMed ID: 2568971
[TBL] [Abstract][Full Text] [Related]
5. Actions of nizatidine, a selective histamine H2-receptor antagonist, on gastric acid secretion in dogs, rats and frogs.
Lin TM; Evans DC; Warrick MW; Pioch RP
J Pharmacol Exp Ther; 1986 Nov; 239(2):406-10. PubMed ID: 2877081
[TBL] [Abstract][Full Text] [Related]
6. The 24-hour acid suppression profile of nizatidine.
Dammann HG; Gottlieb WR; Walter TA; Müller P; Simon B; Keohane P
Scand J Gastroenterol Suppl; 1987; 136():56-60. PubMed ID: 2892256
[TBL] [Abstract][Full Text] [Related]
7. Endocrine effects of a new histamine H2-receptor antagonist, nizatidine (LY139037), in the male rat.
Neubauer BL; Goode RL; Best KL; Hirsch KS; Lin TM; Pioch RP; Probst KS; Tinsley FC; Shaar CJ
Toxicol Appl Pharmacol; 1990 Feb; 102(2):219-32. PubMed ID: 1967857
[TBL] [Abstract][Full Text] [Related]
8. Intravenous nizatidine kinetics and acid suppression.
Callaghan JT; Bergstrom RF; Obermeyer BD; King EP; Offen WW
Clin Pharmacol Ther; 1985 Feb; 37(2):162-5. PubMed ID: 2857117
[TBL] [Abstract][Full Text] [Related]
9. Nizatidine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease.
Price AH; Brogden RN
Drugs; 1988 Nov; 36(5):521-39. PubMed ID: 2905640
[TBL] [Abstract][Full Text] [Related]
10. Twenty four hour intragastric acidity and plasma gastrin concentration in healthy volunteers taking nizatidine 150 mg, nizatidine 300 mg, ranitidine 300 mg, or placebo at 21:00 h.
Lanzon-Miller S; Pounder RE; Chronos NA; Raymond F; Hamilton MR; Dalgleish D
Gut; 1988 Oct; 29(10):1364-9. PubMed ID: 2904394
[TBL] [Abstract][Full Text] [Related]
11. A pharmacokinetic profile of nizatidine in man.
Callaghan JT; Bergstrom RF; Rubin A; Chernish S; Crabtree R; Knadler MP; Obermeyer B; Offen WW; Schneck DW; Aronoff G
Scand J Gastroenterol Suppl; 1987; 136():9-17. PubMed ID: 2892261
[TBL] [Abstract][Full Text] [Related]
12. Effect of a new potent H2-receptor antagonist on meal-stimulated gastric acid secretion and serum gastrin concentration in duodenal ulcer patients.
Brozinsky S; Hogan DL; Isenberg JI; Richardson CT
Dig Dis Sci; 1984 Feb; 29(2):129-33. PubMed ID: 6141898
[TBL] [Abstract][Full Text] [Related]
13. [Effects of nizatidine, a new histamine H2-receptor antagonist, on gastric acid secretion and various gastric and duodenal lesions in rats: comparison with cimetidine].
Okabe S; Takeuchi K; Okada M; Kumadaki Y; Nakata M; Nakata H
Nihon Yakurigaku Zasshi; 1989 Mar; 93(3):133-44. PubMed ID: 2567267
[TBL] [Abstract][Full Text] [Related]
14. The effect of an oral evening dose of nizatidine on nocturnal and peptone-stimulated gastric acid and gastrin secretion.
Kovacs TO; Van Deventer GM; Maxwell V; Sytnik B; Walsh JH
Scand J Gastroenterol Suppl; 1987; 136():41-6. PubMed ID: 2892254
[TBL] [Abstract][Full Text] [Related]
15. Do nizatidine and cimetidine interact with ibuprofen?
Forsyth DR; Jayasinghe KS; Roberts CJ
Eur J Clin Pharmacol; 1988; 35(1):85-8. PubMed ID: 2905991
[TBL] [Abstract][Full Text] [Related]
16. The effect of various dose regimens of famotidine on basal nocturnal and meal-stimulated gastric secretion.
Ryan JR; Chremos AN; Vargas R; Mantell G; Johnson CL; McMahon FG
Clin Pharmacol Ther; 1987 Aug; 42(2):225-31. PubMed ID: 2886245
[TBL] [Abstract][Full Text] [Related]
17. Nizatidine suppression of basal gastric acid output: a comparison of two intravenous dosage regimens.
Danziger L; Furmaga KM; Rodvold KA; Bombeck CT; Fischer JH
J Clin Pharmacol; 1989 Oct; 29(10):946-52. PubMed ID: 2574190
[TBL] [Abstract][Full Text] [Related]
18. Effects of successive doses of nizatidine, cimetidine and ranitidine on serum gastrin level and gastric acid secretion.
Yamaji Y; Omata T; Abe T; Yoshida A; Ueki S; Aita H; Morita H; Chaki K; Segawa Y; Kurimoto T
Arzneimittelforschung; 1991 Sep; 41(9):954-7. PubMed ID: 1796924
[TBL] [Abstract][Full Text] [Related]
19. Rebound nocturnal hypersecretion after four weeks treatment with an H2 receptor antagonist.
Fullarton GM; McLauchlan G; Macdonald A; Crean GP; McColl KE
Gut; 1989 Apr; 30(4):449-54. PubMed ID: 2565860
[TBL] [Abstract][Full Text] [Related]
20. Relationship between steady-state plasma nizatidine concentrations and inhibition of basal and stimulated gastric acid secretion.
Schneck DW; Callaghan JT; Bergstrom RF; Obermeyer BD; Offen WW
Clin Pharmacol Ther; 1990 Apr; 47(4):499-503. PubMed ID: 2109665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
